Overview

CardiacProgenitorcells(CPCs)areabletoproliferateandhavethecapacitytodifferentiateintomaturecardiomyocytes.Thus,thesecellsareattractivetargetsindrugdevelopmentapplicationsforregenerativemedicineprogramsfocusedondevelopingmyocardialinfarctionandcongestiveheartfailuretreatments.Theyarealsoidealforidentifyingandhelpingtoavoiddrug-mediatedcardiacdevelopmentaltoxicityproblemsacrossmultipleprograms,anapplicationforwhichscientistsrequireconsistentanddependableaccesstohumanCPCs.Derivedfromhumaninducedpluripotentstem(iPS)cells,CDI’siCell®CardiacProgenitorCellsprovidearobust,reproducIBLe,andrelevantsourceofcellstoadvancedrugdevelopmentandcardiacregenerativemedicineprograms.Benefitsinclude:•KDR+/PDGFR-α+/c-Kit-humanCPCMarkerprofile•bFGF-mediatedproliferation•WNTinhibitor-mediateddifferentiationintocTNT+cardiomyocytes•High-throughputtargetandphenotypic-basedscreencompatibilityCertainproductsareonlyavailableinselectterritories.PleasecontactyourlocalSalesRepresentativeorProduct&ScientificSupportattechsupport@stemcell.comforfurtherinformation.